A venture capital firm focused on early-stage neuropsychiatric opportunities invests from Pre-Seed to Series A stages, with initial check sizes typically ranging from USD $50K to $1M. The firm is open to acting as the first institutional investor and may provide follow-on capital. The firm is open to both leading and co-investing and will consider board or observer seats on a case-by-case basis. The firm participates in both traditional equity rounds and SAFE agreements. While the firm primarily focuses on U.S.-based companies, the firm is also open to global opportunities.
The firm invests in neuropsychiatric treatments and technologies aimed at improving mental health and general wellness. Areas of interest include psychedelic medicine, brain–computer interfaces, therapeutic platforms, precision diagnostics, and related technologies. For biotech opportunities, the firm prefers assets that are at or near the IND stage. For medtech opportunities, the firm is willing to engage earlier in the development process.
The firm does not have strict requirements regarding management team composition but strongly prefers to work with founders who have prior pharmaceutical or biotech industry experience or a demonstrated track record of successful entrepreneurship.
If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.
Next Phase Newsletter 
Leave a comment